132 related articles for article (PubMed ID: 21083275)
21. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model.
Rohatagi S; Krishnaswami S; Pfister M; Sahasranaman S
Am J Ther; 2005; 12(5):385-97. PubMed ID: 16148423
[TBL] [Abstract][Full Text] [Related]
22. The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide.
Meltzer EO; Derendorf H
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):149-57. PubMed ID: 16937743
[TBL] [Abstract][Full Text] [Related]
23. Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks.
El-Laithy HM; Youssef A; El-Husseney SS; El Sayed NS; Maher A
Drug Deliv; 2021 Dec; 28(1):826-843. PubMed ID: 33928836
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate.
Kaliner MA
Clin Ther; 2006 Mar; 28(3):319-31. PubMed ID: 16750447
[TBL] [Abstract][Full Text] [Related]
25. Ciclesonide: a review of its use in the management of asthma.
Deeks ED; Perry CM
Drugs; 2008; 68(12):1741-70. PubMed ID: 18681495
[TBL] [Abstract][Full Text] [Related]
26. Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids.
Mukker JK; Singh RSP; Derendorf H
J Pharm Sci; 2016 Sep; 105(9):2509-2514. PubMed ID: 27339407
[TBL] [Abstract][Full Text] [Related]
27. An investigation of the pharmacokinetics, pharmacodynamics, safety, and tolerability of ciclesonide hydrofluoroalkane nasal aerosol in healthy subjects and subjects with perennial allergic rhinitis.
Ratner P; Wingertzahn MA; Herzog R; Huang H; Desai SY; Maier G; Nave R
Pulm Pharmacol Ther; 2011 Aug; 24(4):426-33. PubMed ID: 21501692
[TBL] [Abstract][Full Text] [Related]
28. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.
Nave R; Drollmann A; Steinijans VW; Zech K; Bethke TD
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):264-70. PubMed ID: 15968883
[TBL] [Abstract][Full Text] [Related]
29. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.
Rohatagi S; Luo Y; Shen L; Guo Z; Schemm C; Huang Y; Chen K; David M; Nave R; King SP
Am J Ther; 2005; 12(3):201-9. PubMed ID: 15891262
[TBL] [Abstract][Full Text] [Related]
30. [Role of ciclesonide in asthma therapy].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2008; 76(1):37-43. PubMed ID: 18283653
[TBL] [Abstract][Full Text] [Related]
31. Similar Results in Children with Asthma for Steady State Pharmacokinetic Parameters of Ciclesonide Inhaled with or without Spacer.
Boss H; Minic P; Nave R
Clin Med Insights Pediatr; 2010; 4():1-10. PubMed ID: 23761990
[TBL] [Abstract][Full Text] [Related]
32. Ciclesonide: a novel inhaled corticosteroid for asthma.
Christie P
Drugs Today (Barc); 2004 Jul; 40(7):569-76. PubMed ID: 15510231
[TBL] [Abstract][Full Text] [Related]
33. LC-HRMS/MS study of the prodrug ciclesonide and its active metabolite desisobutyryl-ciclesonide in plasma after an inhalative administration to horses for doping control purposes.
Trevisiol S; Moulard Y; Kaabia Z; Delcourt V; Loup B; Garcia P; Boyer S; Dauriac K; Groseille G; Rouger S; Narbe R; Popot MA; Bailly-Chouriberry L
Drug Test Anal; 2022 Feb; 14(2):252-261. PubMed ID: 34634175
[TBL] [Abstract][Full Text] [Related]
34. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue.
Mutch E; Nave R; McCracken N; Zech K; Williams FM
Biochem Pharmacol; 2007 May; 73(10):1657-64. PubMed ID: 17331475
[TBL] [Abstract][Full Text] [Related]
35. Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding.
Wu K; Blomgren AL; Ekholm K; Weber B; Edsbaecker S; Hochhaus G
Drug Metab Dispos; 2009 Jul; 37(7):1421-6. PubMed ID: 19364829
[TBL] [Abstract][Full Text] [Related]
36. Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog.
Guo Z; Gu Z; Howell SR; Chen K; Rohatagi S; Cai L; Wu J; Stuhler J
Am J Ther; 2006; 13(6):490-501. PubMed ID: 17122529
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide.
Stoeck M; Riedel R; Hochhaus G; Häfner D; Masso JM; Schmidt B; Hatzelmann A; Marx D; Bundschuh DS
J Pharmacol Exp Ther; 2004 Apr; 309(1):249-58. PubMed ID: 14718604
[TBL] [Abstract][Full Text] [Related]
38. Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa.
Sato H; Nave R; Nonaka T; Yoshihisa N; Atsuhiro N; Mochizuki T; Takahama S; Kondo S; Wingertzahn M
BMC Pharmacol; 2007 Jun; 7():7. PubMed ID: 17553148
[TBL] [Abstract][Full Text] [Related]
39. Nasal distribution of budesonide inhaled via a powder inhaler.
Thorsson L; Newman SP; Weisz A; Trofast E; Morén F
Rhinology; 1993 Mar; 31(1):7-10. PubMed ID: 8321983
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous determination of ciclesonide and its active metabolite desisobutyryl-ciclesonide in human plasma by LC-APCI-MS/MS: application to pharmacokinetic study in healthy Chinese volunteers.
Su MX; Song M; Zhuang Y; Wang YQ; Hang TJ
J Pharm Biomed Anal; 2011 Apr; 55(1):230-5. PubMed ID: 21296519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
